Published
March 1, 2025
Updated
July 27, 2026
This settlement resolves claims that the at-home health testing brands Everlywell and Natalist let third-party tracking tools on their websites transmit customer information to Meta and Google. Claims closed in March 2025 and the court entered a final approval order, so this page now tracks where the $5 million fund stands.
Current Status
Claims are closed. The deadline to submit a claim form was March 19, 2025, and new claims are no longer accepted. The U.S. District Court for the Northern District of Illinois entered a final approval order, which the settlement administrator reported as of May 1, 2025. Under the settlement's terms, payments begin after the appeal period concludes. No official payment-completion date had been announced as of July 27, 2026. People who filed should rely on the official settlement website and on communications tied to their own claim.StatusFinal Approval GrantedPayments follow the conclusion of the appeal period.
Claim DeadlineMarch 19, 2025New claims are not accepted.
Settlement Fund$5,000,000$2.64M for the sensitive-test subclass and $2.36M for the non-sensitive subclass.
Proof RequiredYesA Class Member ID from the notice was required to file online.
What Was the Case About?
Plaintiffs alleged that Everlywell and its Natalist brand installed third-party tracking tools — including advertising pixels built by Meta and Google — on their websites, and that those tools transmitted information about customers, including personally identifiable information tied to the tests they bought, to Facebook and Google without proper authorization. The defendants denied the allegations and agreed to the settlement to resolve the claims without any admission of wrongdoing.Everlywell and Natalist both sell at-home health testing and reproductive-health products, which is why the settlement drew a distinction between sensitive and non-sensitive tests when allocating the fund.
Who Was Covered?
The class covered people who purchased a product or service from Everlywell.com or Natalist.com between April 4, 2019 and December 3, 2024. Members were sorted into two subclasses based on what they bought.• Sensitive Test Subclass — approximately 660,000 people who purchased tests treated as sensitive, such as tests for sexually transmitted infections. Allocation: $2.64 million.
• Non-Sensitive Test Subclass — approximately 1.34 million people who purchased other tests. Allocation: $2.36 million.
How Much Could Class Members Get?
Payments are pro rata within each subclass, so the per-person amount depends on how many valid claims were approved in that subclass after court-approved fees, costs and administration expenses were deducted. Members of the sensitive-test subclass draw from a larger allocation shared among a smaller group, so their share was expected to be higher. No fixed per-person figure was published.What Proof Was Required?
Filing online required the Class Member ID printed on the notice the administrator sent, which is why this page is marked Proof Required: Yes even though no receipts or purchase documentation were needed. Class members who could not locate their ID were directed to the official settlement website rather than to any other contact channel.What Happens Next?
With a final approval order entered, the remaining steps are the conclusion of the appeal period and the administrator's distribution of the net fund to approved claimants. No payment date had been announced as of July 27, 2026. Updates are posted on the official settlement website.Official information is available at EW Lab Test Settlement.
Important Dates
• Class period: April 4, 2019 through December 3, 2024• Claim deadline: March 19, 2025
• Final approval order: entered, reported as of May 1, 2025
• Payments: after the appeal period concludes
Sources
• Official settlement website: EW Lab Test Settlement• Settlement notice, claim form and final approval order posted by the settlement administrator
• Reedy, et al. v. Everlywell, Inc., No. 1:24-cv-02713, U.S. District Court for the Northern District of Illinois
For more class actions keep scrolling below.
Settlement Fund
$5,000,000
Case Title
Reedy, et al. v. Everlywell, Inc.
Case Number
1:24-cv-02713
Court
U.S. District Court for the Northern District of Illinois
Claim Deadline
March 19, 2025
Status
Final Approval Granted — payments follow the appeal period
Official Website
EW Lab Test Settlement
